Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
M126999-200mg | 200mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $46.90 | |
M126999-1g | 1g | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $151.90 | |
M126999-5g | 5g | In stock | $402.90 | |
M126999-25g | 25g | In stock | $1,409.90 |
PR and GR antagonist
Synonyms | mifepristone|84371-65-3|Mifegyne|Mifeprex|RU-486|Korlym|RU486|RU 486|RU 38486|Mifepriston|Corlux|RU-38486|Mifepristona|Mifepristonum|Mifepristonum [Latin]|C29H35NO2|HSDB 6841|UNII-320T6RNW1F|BRN 5779404|320T6RNW1F|CCRIS 9332|DTXSID5023322|RU 486-6|CHEBI:5 |
---|---|
Specifications & Purity | ≥98% |
Storage Temp | Store at 2-8°C |
Shipped In | Wet ice |
Grade | Moligand™ |
Action Type | AGONIST, ANTAGONIST |
Mechanism of action | Progesterone receptor antagonist |
Product Description | Mifepristone is a remarkably active antagonist of progesterone receptor and glucocorticoid receptor with IC50 of 0.2 nM and 2.6 nM, respectively. |
ALogP | 3.8 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one |
---|---|
INCHI | InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1 |
InChi Key | VKHAHZOOUSRJNA-GCNJZUOMSA-N |
Canonical SMILES | CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O |
Isomeric SMILES | CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O |
WGK Germany | 3 |
RTECS | KG2955000 |
PubChem CID | 55245 |
Molecular Weight | 429.59 |
Reaxy-Rn | 5779404 |
DrugBank Ligand | DB00834 |
---|---|
PubChem CID | 55245 |
BindingDB Ligand | 18627 |
Wikipedia | Mifepristone |
CAS Registry No. | 84371-65-3 |
ChEMBL Ligand | CHEMBL1276308 |
ChEBI | CHEBI:50692 |
NURSA Ligand | 10.1621/ST5A19ZOKW |
RCSB PDB Ligand | 486 |
PEP | mifepristone |
DrugCentral Ligand | 1805 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
I2226309 | Certificate of Analysis | Jul 10, 2024 | M126999 |
I2226306 | Certificate of Analysis | Jul 04, 2024 | M126999 |
G2417847 | Certificate of Analysis | Jun 29, 2024 | M126999 |
G2417853 | Certificate of Analysis | Jun 29, 2024 | M126999 |
G2417854 | Certificate of Analysis | Jun 29, 2024 | M126999 |
G2417855 | Certificate of Analysis | Jun 29, 2024 | M126999 |
G2417856 | Certificate of Analysis | Jun 29, 2024 | M126999 |
I2226305 | Certificate of Analysis | Jul 22, 2022 | M126999 |
L2307160 | Certificate of Analysis | Jul 22, 2022 | M126999 |
Solubility | Soluble in water (partly), DMF (~30 mg/ml), ethanol (50 mg/ml), methanol, and DMSO (86 mg/ml at 25 °C).(Soluble): chloroform |
---|---|
Sensitivity | Heat sensitive |
Specific Rotation[α] | 141° (C=0.5,CHCl3) |
Melt Point(°C) | 195 °C |
Pictogram(s) | GHS08, GHS07 |
---|---|
Signal | Danger |
Hazard Statements | H302:Harmful if swallowed H312:Harmful in contact with skin H332:Harmful if inhaled H360:May damage fertility or the unborn child H362:May cause harm to breast-fed children |
Precautionary Statements | P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P260:Do not breathe dust/fume/gas/mist/vapors/spray. P271:Use only outdoors or in a well-ventilated area. P270:Do not eat, drink or smoke when using this product. P304+P340:IF INHALED: Remove person to fresh air and keep comfortable for breathing. P362+P364:Take off contaminated clothing and wash it before reuse. P330:Rinse mouth. P263:Avoid contact during pregnancy/while nursing. P203:Obtain, read and follow all safety instructions before use. P301+P317:IF SWALLOWED: Get medical help. P318:if exposed or concerned, get medical advice. P317:Get emergency medical help. |
WGK Germany | 3 |
RTECS | KG2955000 |
Reaxy-Rn | 5779404 |
Merck Index | 6186 |
Starting at $47.90
1. Shannon S et al.. (2015) Dexamethasone-Mediated Activation of Fibronectin Matrix Assembly Reduces Dispersal of Primary Human Glioblastoma Cells.. PLoS One, 10 (8): (e0135951). [PMID:26284619] |
2. Nair M et al.. (2018) Dexamethasone-Mediated Upregulation of Calreticulin Inhibits Primary Human Glioblastoma Dispersal Ex Vivo.. Int J Mol Sci, 19 (2): [PMID:29443896] |
3. Zhang B et al.. (2020) Corticosteroid receptor rebalancing alleviates critical illness-related corticosteroid insufficiency after traumatic brain injury by promoting paraventricular nuclear cell survival via Akt/CREB/BDNF signaling.. J Neuroinflammation, 17 (318). [PMID:33100225] |
4. Wang C et al.. (2017) Experimental research on the relationship between the stiffness and the expressions of fibronectin proteins and adaptor proteins of rat trabecular meshwork cells.. BMC Ophthalmol, 17 (268). [PMID:29284449] |
5. Karami Kheirabad M et al.. (2015) Expression of Melanocortin-4 Receptor mRNA in Male Rat Hypothalamus During Chronic Stress.. Int J Mol Cell Med, 4 (3): (182-7). [PMID:26629487] |
6. Xiao R et al.. (2016) Environmental and Genetic Activation of Hypothalamic BDNF Modulates T-cell Immunity to Exert an Anticancer Phenotype.. Cancer Immunol Res, 4 (6): (488-497). [PMID:27045020] |